CPE-KP 20年演變暨各級生技藥廠市場准入策略探討

Abstract

抗藥性細菌已成為全球公共衛生的重大威脅，其中產碳青黴烯酶克雷白氏肺炎桿菌（CPE-KP）尤具臨床急迫性。本研究以「CPE-KP 二十年演變暨各級生技藥廠市場准入策略」為主題，採解釋性序列混合研究設計（量化→質性→整合），結合階層式次群組統合分析、策略群組分析與半結構式專家訪談，建構「需求—供給—治理」三軸證據鏈。 量化結果顯示，臺灣 CPE-KP 之基因型已由 KPC 單一主導，轉為 KPC、OXA-48-like 與 MBL 共存之多元化格局（KPC 與 OXA-48 時序差異均達顯著，KPC p = 0.0482、OXA-48 p = 0.0083），並呈現明顯之南北、東西地理差異；末線抗生素抗藥性與 CRKP 菌血症死亡率（合併估計 0.59）持續高居不下。Pipeline 分析揭示供需失衡之結構性悖論：具 MBL 覆蓋之高創新藥物仍停留自費階段，形成顯著可及性鴻溝。專家訪談並補充地緣政治授權、跨部會治理、醫療階層與精準診斷推動等四項量化未及之關鍵變數。 綜整三大證據鏈，本研究提出「藥物韌性策略模型」（DRSM）與廣義公私協力治理架構（Pipelines＋Policy＋Protocol），主張由各級生技藥廠與感染症醫學會共組抗生素管理（AMS）平台，將宏觀治理轉化為可執行之臨床處置，協助臺灣由被動反應之舊體制，重構為「精準診斷、精準給付、精準供應」之高韌性生物安全防禦體系。

Carbapenemase-producing Klebsiella pneumoniae (CPE-KP) poses an urgent clinical threat. Using an explanatory sequential mixed-methods design, this study combines a hierarchical subgroup meta-analysis, strategic group analysis, and expert interviews to build a “demand–supply–governance” evidence chain on the twenty-year evolution of CPE-KP and biotech firms’ market access strategies. Quantitatively, Taiwan’s CPE-KP genotypes have shifted from KPC dominance to coexistence of KPC, OXA-48-like, and MBL (temporal differences significant: KPC p = 0.0482, OXA-48 p = 0.0083), with marked geographic disparities; last-line resistance and CRKP bacteremia mortality (pooled 0.59) stay high. Pipeline analysis reveals a supply–demand paradox: innovative MBL-active agents remain out-of-pocket, creating an accessibility gap. Interviews add four overlooked variables—geopolitical licensing blockage, cross-ministerial governance failure, healthcare-tier disparity, and slow precision-diagnostics adoption. Integrating these findings, the study proposes a Drug Resilience Strategy Model (DRSM) and a broad Public-Private Partnership framework (Pipelines + Policy + Protocol), recommending that biotech firms and the Infectious Diseases Society co-establish an Antimicrobial Stewardship (AMS) platform to turn macro governance into executable clinical protocols—transforming Taiwan toward a resilient biosecurity system of precise diagnosis, reimbursement, and supply.